Kairos Pharma Ltd., a biopharmaceutical company specializing in oncology therapeutics, will present its research strategy at the D. Boral Capital Inaugural Global Conference in New York City. CEO and Chairman John Yu will conduct investor meetings to discuss the company's groundbreaking approach to addressing cancer treatment challenges.
The conference presents a critical platform for Kairos Pharma to showcase its lead candidate, ENV105, an antibody targeting CD105—a protein responsible for drug resistance in cancer treatments. By focusing on reversing drug resistance, the company aims to enhance the effectiveness of standard cancer therapies across multiple cancer types.
Currently, ENV105 is undergoing clinical trials in two critical areas: a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials represent significant potential in addressing substantial unmet medical needs in oncology treatment.
The conference provides an essential opportunity for investors to gain insights into Kairos Pharma's innovative approach to overcoming cancer treatment limitations. By utilizing structural biology techniques, the company is developing strategies to combat immune suppression and drug resistance, potentially transforming cancer treatment protocols.
